- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04515615
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
March 10, 2023 updated by: Yu jiren
A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
This study is a prospective, single arm, multi-center phase II clinical trial.
The primary study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule plus oxaliplatin and Camrelizumab as adjuvant therapy in stage III gastric cancer, including the incidences and types of adverse events.
The secondary study objective is to observe and evaluate the disease-free survival (DFS), overall survival (OS) and treatment completion rate.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
- Study population: participants with stage III gastric cancer confirmed by postoperative pathology according to American Joint Committee on Cancer (AJCC) / Union for International Cancer Control (UICC) 8th Tumor Node Metastasis (TNM) staging classification.
- Sample size: single arm design was used in this study and 52 participants were estimated to be enrolled.
- Research content: In this study, within 4-6 weeks after the completion of the operation, the participants were selected and qualified for this study, and were scheduled to receive 200mg camrelizumab once intravenous infusion on the first day (q3w), then 130mg/m^2 oxaliplatin on the first day (q3w), and tegafur gimeracil oteracil potassium capsule was taken as follow: surface area is less than 1.25, 80mg per day, twice a day; ≥1.25 ~ <1.5, 100mg per day, twice a day; ≥1.5, 120mg per day, twice a day, and oral administration for 1-14 days every 3 weeks. Three weeks as a course of treatment, a total of 8 courses, after treatment, safety visit and survival follow-up will be carried out. A total of 3 years follow-up time is scheduled since the first medication, and the frequency is once every 3-6 months within 2 years, and once every 6-12 months for the third year.
- Adverse events (AEs) management: To minimize the risk of AEs, the investigators will monitor carefully to determine whether or not they are within the expected range. The degree of AEs is evaluated according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.0). Investigators will also conduct a thorough examination and adopt an appropriate system to take any necessary measures to deal with AEs.
Study Type
Interventional
Enrollment (Anticipated)
52
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiren Yu
- Phone Number: 0086-0571-87236147
- Email: yujr0909@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Lishui, Zhejiang, China, 323000
- Lishui Central Hospital
-
Taizhou, Zhejiang, China, 317000
- Taizhou Hospital
-
Wenzhou, Zhejiang, China, 325027
- The Second Affiliated Hospital of Wenzhou Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF).
- The gender is not limited. Age: ≥ 18 years and ≤ 75 years old.
- Gastric or gastroesophageal junction adenocarcinoma confirmed by pathology.
- Without evidence of distant metastatic disease before operation by imaging.
- Received D2 or D2+ radical gastrectomy by open surgery (R0 resection).
- Stage III gastric cancer confirmed by postoperative pathology (AJCC/UICC 8th TNM staging classification).
- Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment.
- Life expectancy ≥ 6 months.
The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of blood transfusion, albumin, recombinant human thrombopoietin or granulocyte stimulating factor):
A. Hematological function:
- White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L;
- Absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L;
- Platelet count (PLT) ≥ 100 × 10 ^ 9 / L;
- Hemoglobin (Hb) ≥ 90 g / L.
B. Hepatic function:
- Total bilirubin (TBIL) ≤ 1.5 × ULN (upper limit of normal);
- Aspartate aminotransferase (AST) ≤ 2.5 × ULN;
- Alanine aminotransferase (ALT) ≤ 2.5 × ULN;
- Albumin (ALB) ≥ 30 g / L.
C. Renal function:
- Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 60 ml / min for those with creatinine level > 1.5 × ULN.
D. Coagulation function:
- International normalized ratio (INR) ≤ 1.5;
- Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- Female of childbearing age must meet requirements: urine pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of camrelizumab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of camrelizumab, or 180 days after the last dose of chemotherapy, whichever is longer).
Exclusion Criteria:
- Received previous chemotherapy, radiotherapy, targeted therapy or immunotherapy.
- Previous or concurrent have other active malignant tumors (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy).
- Existence of unrecovered complications after radical gastrectomy before the first dose of study treatment (including but not limited to: infection, gastrointestinal bleeding/ obstruction, anastomotic fistula, pancreatic fistula and anastomotic stenosis).
- Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV), echocardiogram shows left ventricular ejection fraction (LVEF) < 50%.
- Existence of chronic diarrhea (watery diarrhea: ≥ 5 times per day).
- Participants with active infection within 14 days before the first dose of study treatment which need medical intervention.
- Participants with active tuberculosis.
- Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms.
- Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody.
- Females who are pregnant or breastfeeding or expecting to conceive during the study period.
- Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period.
- Concurrent or previous have severe allergic reaction to any antibody-based drugs.
- Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia).
- Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza.
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc.
- Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Camrelizumab and chemotherapy
Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days.
Three weeks as a course of treatment, a total of 8 courses.
|
Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks.
Repeated every 21 days.
21 days for a cycle.
Other Names:
Oxaliplatin: 130 mg/m^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks.
Repeated every 21 days, 21 days for a cycle.
Tegafur gimeracil oteracil potassium capsule: 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days.
Repeated every 21 days.
21 days for a cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidences and types of adverse events
Time Frame: 9 months
|
The incidences and types of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival (DFS)
Time Frame: 3 years
|
Disease-free survival (DFS)
|
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
Overall survival (OS)
|
3 years
|
Treatment completion rate
Time Frame: 6 months
|
Percentage of participants who complete eight cycles of chemotherapy in combination with Camrelizumab.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 9, 2020
Primary Completion (Anticipated)
September 9, 2023
Study Completion (Anticipated)
September 1, 2025
Study Registration Dates
First Submitted
August 14, 2020
First Submitted That Met QC Criteria
August 14, 2020
First Posted (Actual)
August 17, 2020
Study Record Updates
Last Update Posted (Actual)
March 13, 2023
Last Update Submitted That Met QC Criteria
March 10, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Oxaliplatin
- Tegafur
Other Study ID Numbers
- IIT20200046C-R1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer Stage III
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditionsUnited States
-
Thomas Jefferson UniversitySuspendedMalignant Solid Neoplasm | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Colorectal Adenocarcinoma | Small Intestinal Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
AIPING ZHOURecruitingGastric Cancer Stage III | Gastric Cancer Stage IIChina
-
National Cancer Institute (NCI)CompletedStage IV Gastric Cancer | Stage III Gastric CancerUnited States
Clinical Trials on Camrelizumab
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Peking UniversityNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingNasopharyngeal Carcinoma | Oligometastasis | RadiotherapyChina
-
Fudan UniversityRecruiting
-
Fujian Medical University Union HospitalRecruitingRadiotherapy | Immunotherapy | Esophageal NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Henan Provincial People's HospitalNot yet recruiting